triamcinolone acetonide (Azmacort 134a / KI03216 / Azmacort CFC)

Real-World Anatomical Outcomes of Suprachoroidal Triamcinolone Acetonide Injections in a Large Retinal Practice over a 4-Year Period.

Miller Chase W CW, Scroggins Casey A CA, Wuller Shannon L SL, Hegarty Marcella J MJ et al.

To evaluate the clinical role, durability, anatomical response, and safety for suprachoroidal triamcinolone acetonide (SCTA) (Xipere) in routine clinical practice. Data were manually extracted from health records at a high-volume retina practice in Cleveland, Ohio. All patients with noninfectious inflammatory macular edema undergoing SCTA (≥1 billing code) between October 25, 2021, and July 17, 2025, were included. Patients with known systemic autoimmune or infectious associations were excluded. Unique eyes were defined by MRN + laterality, with "OU" entries split into OD/OS. Patient demographics, underlying diagnosis categorization, time between first and second injection (for eyes with ≥2 injections) were summarized. Pre- versus post-treatment central retinal thickness (CRT) and intraocular pressure (IOP) were compared via paired t-tests. A total of 177 patients (195 eyes) received 340 SCTA injections for macular edema associated with an underlying diagnosis of intermediate uveitis (10%), pseudophakic cystoid macular edema (31%), and posterior uveitis (59%). The time between first and second injection was approximately 5 months [SD ± 72.5; median 144 (min 35, max 427)]. From baseline to follow-up, mean CRT decreased by 103 µm [95% CI: (-122,-83.2), P < 0.001], while IOP increased minimally [mean difference 0.7 mmHg, 95% CI: (-0.02, 1.43), P = 0.057]; and was medically managed when elevated. In this real-world cohort, findings suggest that SCTA achieves robust anatomical improvement, a favorable IOP profile, and prolonged durability across patients with inflammation-related macular edema.

Selective laser trabeculoplasty is effective in controlling steroid-induced OHT after 0.19 µg Fluocinolone acetonide implant, a long-term outcome of 15 eyes.

Chacun Samuel S, Billant Jeremy J, Goissaud Axel A, Chirpaz Nicolas N et al.

To evaluate the long-term effectiveness and safety of selective laser trabeculoplasty (SLT) for controlling intraocular pressure (IOP) in patients with steroid-induced ocular hypertension (OHT) treated with fluocinolone acetonide (FAc) intravitreal implants. This was a single-center retrospective case series of patients with steroid-induced OHT. Eligibility required prior to exposure to ≥ 3 sustained-release dexamethasone intravitreal implants per eye. SLT was performed in all eyes either before (group 1, n = 6), after (group 2, n = 6), or both before and after (group 3, n = 3) the FAc implantation. IOP was analysed with linear mixed-effects models (random intercept for eye). The mean IOP and within-eye variability (SD-IOP) were summarized for the pre-SLT and post-SLT periods. Fifteen eyes from thirteen patients treated for macular edema were followed for 32 ± 17.7 months after SLT. The mean IOP decreased by 14.2 mmHg across the cohort (p < 0,001). In group 1, which was treated with SLT before FAc implantation, the mean IOP decreased from 16.5 ± 4.8 mmHg to 13.7 ± 2.1 mmHg (p < 0.001) with significantly reduced IOP variability (-2.1 mmHg, p < 0.001). No eye required filtering surgery. Steroid-induced OHT resolved in all eyes within ≤ 4 months after the last dexamethasone implant and ≤ 36 months after the FAc implant. SLT is a safe, effective, and repeatable intervention for preventing or controlling IOP elevation in OHT responders' eyes receiving FAc implants. Performing SLT prior to FAc injection may offer better IOP control and reduce variability in such patients.

Re: Singer et al.: Fluocinolone acetonide implant as a baseline therapy for diabetic macular edema: results from the randomized phase 4 NEW DAY study (Ophthalmology. 2026;133:837-851).

Jummala Sasikala S, C Mohana Kumari MK, Tripathi Soumya S, Sati Deepti M DM

Platelet-rich plasma (PRP) versus steroid as an intradiscal injection for lower back aches among degenerative disc disorder patient in India.

Singh Jaideep J, Keshari Urmila U, Vignesh Rajan V V, Sivakumar Sivasamy S et al.

Degenerative disc disease (DDD) is a major cause of chronic low back pain and optimal minimally invasive treatment remains uncertain. Therefore, it is of interest to compare the efficacy of intradiscal platelet-rich plasma (PRP) versus steroid injections using Visual Analog Scale (VAS) scores. In this prospective study of 60 patients, participants were randomized to receive either triamcinolone or PRP injections weekly for three weeks, with follow-up at two and six months. Steroid injections provided greater short-term pain relief at two months, whereas PRP showed significantly superior pain reduction at six months with lower final VAS scores. Both modalities are effective in the short term, but PRP offers better sustained pain relief and may be preferred for long-term management of degenerative disc disease.